Search
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalThe phase II of the same study showed that in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (NSCLC), adagrasib was efficient without new safety signals. … Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics.
Ospemifene
go.drugbank.com/drugs/DB04938ApprovedFDA approved on February 26, 2013. … Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Lenograstim
go.drugbank.com/drugs/DB13144ApprovedWithdrawnLenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Misoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] … [L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the
Categories: Prostaglandin E1 Analog, Prostaglandins E, SyntheticMethimazole
go.drugbank.com/drugs/DB00763ApprovedInvestigational[L8336,L8339] On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [propylthiouracil],[L8339] and is the active metabolite of the … [A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigational[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic
Zidebactam
go.drugbank.com/drugs/DB13090Approved[L63350] It is available only in fixed combination with [cefepime], which binds PBP3 and PBP1a/b. … [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated
Isosorbide
go.drugbank.com/drugs/DB09401ApprovedInvestigationalIsosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. … Currently, isosorbide is an organic nitrate currently available in the [isosorbide mononitrate] and [isosorbide dinitrate] forms, and is used for the prevention of angina.
Thymidine
go.drugbank.com/drugs/DB04485ApprovedInvestigational[A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the … [A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent.